RxDoctor Payments Data

Donald Berry, MD

Pulmonary Disease · Bellingham, WANPI 1578569927

Payments from drug & device makers

$1,096in general payments, 2019–2025

Across 18 payments — averaging $60.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$785
  • Boehringer Ingelheim$83
  • AstraZeneca$81
  • Genentech USA, Inc.$40
  • Sanofi$39
  • Insmed, Inc.$25
  • plus $43 from 3 others

What the payments were for

  • Travel & lodging$52648%
  • Food & beverage$51547%
  • Education$555%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,096 in reported general payments places this provider in the 60th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$78,549
Medicare patients
472
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate37$480,396
Prolastin CAlpha-1-Proteinase Inhibitor13$182,494
Stiolto RespimatTiotropium Br/Olodaterol Hcl67$59,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$56,441
Advair HfaFluticasone Propion/Salmeterol97$45,280
Spiriva RespimatTiotropium Bromide44$34,797
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$33,165
Breo ElliptaFluticasone/Vilanterol26$22,953
Spiriva HandihalerTiotropium Bromide17$17,139
Incruse ElliptaUmeclidinium Bromide15$9,347
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$8,996
Albuterol Sulfate HfaAlbuterol Sulfate175$7,411
SymbicortBudesonide/Formoterol Fumarate14$6,133
Arnuity ElliptaFluticasone Furoate18$4,869
Wixela InhubFluticasone Propion/Salmeterol16$3,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$83$575,064148 claims
AstraZenecaSymbicort$81$6,13314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 275 pulmonary disease providers in Washington.

Other pulmonary disease in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →